CAG
NAVB

Csenge Advisory Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Csenge Advisory Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,000
Closed -$4K – 222
2018
Q4 		$4K Buy
+2,000
New +$8.24K ﹤0.01% 188

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Csenge Advisory Group's NAVB Position: Q1 2019 in Review

Csenge Advisory Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2019, closing a stake of 2,000 shares — an estimated $4K sold.

Csenge Advisory Group first reported a position in NAVB in Q4 2018 and held it in 1 quarter. The position peaked at $4K in Q4 2018. 49 funds tracked by Wall St. Rank hold NAVB as of Q1 2019.

  • Csenge Advisory Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2019 after selling out during the quarter.
  • Csenge Advisory Group sold 2,000 Navidea Biopharmaceuticals Inc. shares in Q1 2019, an estimated $4K.
  • Csenge Advisory Group first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Navidea Biopharmaceuticals Inc. position peaked at $4K in Q4 2018.
  • 49 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2019.

Based on Csenge Advisory Group's 13F filing for Q1 2019, filed 7 May 2019.